ITP - Immune Thrombocytopenia: Clinical Trials

19 trials for ITP - Immune Thrombocytopenia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 5 not yet recruiting, 3 unknown, 2 withdrawn. 6 Phase 2, 4 Phase 1, 3 Not applicable, 2 Phase 3, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 26Recruiting 3, Not yet recruiting 2, Unknown 1
Phase 14Recruiting 3, Withdrawn 1
Not applicable3Not yet recruiting 1, Recruiting 1, Withdrawn 1
Phase 32Not yet recruiting 1, Recruiting 1
Phase 42Recruiting 2

Follow ITP - Immune Thrombocytopenia: new trials by email Literature Review of ITP - Immune Thrombocytopenia trials Research Report on ITP - Immune Thrombocytopenia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia
Phase 1 / Phase 2RecruitingCRISPR Therapeutics AG602026-07-172026-10-20
TPO-RA Plus Baricitinib vs. TPO-RA for ITP
Baricitinib, TPO-RA - ITP - Immune Thrombocytopenia
Phase 2Not yet recruitingPeking University People's Hospital1002026-07-012026-06-25
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
standard-dose methylprednisolone/prednisone., thrombopoietin receptor agonist(TPO-RA), including but not limited to hetrombopag or eltrombopag., rituximab. - ITP - Immune Thrombocytopenia
Phase 4RecruitingInstitute of Hematology & Blood Diseases Hospital, China382026-06-222026-08-26
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
Avatrombopag+All trans retinoic acid, Avatrombopag - ITP - Immune Thrombocytopenia
Phase 2 / Phase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2482025-12-012025-12-12
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
Phase 2 / Phase 3Recruitingargenx242025-10-202026-11-16
"Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children"
ITP - Immune Thrombocytopenia
Not yet recruitingSohag University802025-08-202025-06-17
OM336 in Autoimmune Cytopenias
OM336 - AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
Phase 1RecruitingLakefront Biotherapeutics West LLC322025-08-012026-09-03
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Eltrombopag - ITP - Immune Thrombocytopenia
Not applicableRecruitingSohag University1002025-07-142025-07-30
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
Avatrombopag 20 mg Oral Tablet - ITP - Immune Thrombocytopenia
Phase 4RecruitingAl-Mustansiriyah University252025-06-082025-08-21
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
Ripertamab/Eltrombopag, Eltrombopag - ITP - Immune Thrombocytopenia
Not applicableNot yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology782025-02-012025-01-24
Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
MSC - ITP - Immune Thrombocytopenia
Not applicableWithdrawnGuangzhou Bio-gene Technology Co., Ltd2024-11-112026-05-28
RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
ITP - Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP)
RecruitingFundación Española de Hematología y Hemoterapía10002024-09-272025-04-09
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
HMPL-523 - Immune Thrombocytopenia, Blood Platelet Disorder
Phase 1WithdrawnHutchmed2024-04-022025-09-16
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
CAR-T cells - ITP - Immune Thrombocytopenia
Phase 1 / Phase 2Recruiting920th Hospital of Joint Logistics Support Force of People's Liberation Army of China102024-02-012024-07-22
Immune Markers in Pediatric ITP on Second Line Therapy
complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ. - ITP - Immune Thrombocytopenia
UnknownAssiut University422024-01-012023-11-14
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura
eltrombopag and romiplastim - ITP - Immune Thrombocytopenia
Not yet recruitingAssiut University1002023-12-012023-11-18
High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial
hetrombopag 5mg po qd, High-dose Dexamethasone - ITP - Immune Thrombocytopenia
Phase 2UnknownShandong University1002023-09-152023-09-26
Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP
Fostamatinib - ITP - Immune Thrombocytopenia, Chronic ITP
CompletedGruppo Italiano Malattie EMatologiche dell'Adulto952023-05-052025-04-30
Explore the Relationship Between Platelet Count and Bleeding Score in ITP
ITP - Immune Thrombocytopenia
UnknownAssiut University1002022-04-102024-02-23

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (19)  ·  Thrombocytopenia (2)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Autoimmune Diseases (1)  ·  Blood Coagulation Disorders (1)  ·  Blood Platelet Disorders (1)  ·  Hematologic Diseases (1)  ·  Hemorrhage (1)  ·  Hemorrhagic Disorders (1)  ·  Immune System Diseases (1)  ·  Pathologic Processes (1)  ·  Purpura (1)  ·  Purpura, Thrombocytopenic (1)  ·  Skin Manifestations (1)  ·  Thrombotic Microangiopathies (1)

Broader conditions

Cytopenia (19)  ·  Hemic and Lymphatic Diseases (19)  ·  Pathological Conditions, Signs and Symptoms (19)  ·  Signs and Symptoms (19)  ·  Autoimmune Diseases (18)  ·  Blood Coagulation Disorders (18)  ·  Blood Platelet Disorders (18)  ·  Hematologic Diseases (18)  ·  Hemorrhage (18)  ·  Hemorrhagic Disorders (18)  ·  Immune System Diseases (18)  ·  Pathologic Processes (18)  ·  Purpura (18)  ·  Purpura, Thrombocytopenic (18)  ·  Skin Manifestations (18)

Interventions

eltrombopag (5)  ·  avatrombopag (2)  ·  hetrombopag (2)  ·  Adrenal Cortex Hormones (1)  ·  Blood Cell Count (1)  ·  CD4 Lymphocyte Count (1)  ·  Dexamethasone (1)  ·  Immunotherapy, Adoptive (1)  ·  Methylprednisolone (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  Tablets (1)  ·  baricitinib (1)  ·  daratumumab (1)  ·  fostamatinib (1)

Sponsors

Assiut University (3)  ·  Institute of Hematology & Blood Diseases Hospital, China (2)  ·  Sohag University (2)  ·  920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1)  ·  Al-Mustansiriyah University (1)  ·  CRISPR Therapeutics AG (1)  ·  Fundación Española de Hematología y Hemoterapía (1)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (1)  ·  Guangzhou Bio-gene Technology Co., Ltd (1)  ·  Hutchmed (1)  ·  Lakefront Biotherapeutics West LLC (1)  ·  Peking University People's Hospital (1)  ·  Shandong University (1)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)  ·  argenx (1)

Countries

China (4)  ·  Spain (4)  ·  Germany (3)  ·  United States (3)  ·  Australia (2)  ·  Egypt (2)  ·  Italy (2)  ·  France (1)  ·  Iraq (1)  ·  Japan (1)  ·  Lithuania (1)  ·  Norway (1)  ·  Poland (1)  ·  Romania (1)  ·  Serbia (1)

Top investigators

Azhar A Mohammed, M.D. (1)  ·  Francesco Zaja (1)  ·  Khaled I El-sayeh, M.D. (1)  ·  Lei Zhang (1)  ·  Mostafa M Embaby, M.D. (1)  ·  Rania Mohammed Mahmoud Hafez, professor (1)  ·  Sanbin Wang, Doctor (1)  ·  William Schelman, MD, PhD (1)  ·  Yousreyia Abdel Rahman Ahmed, professor (1)

NIH funding

2025 (1)